Atara Biotherapeutics (ATRA) Assets Average (2014 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Assets Average came in at $20.1 million in Q1 2026, down 76.49% YoY from $85.6 million in Q1 2025, and down 20.18% on a QoQ basis from $25.2 million in Q4 2025.
Atara Biotherapeutics (ATRA) Assets Average (2014 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 13 years of Assets Average data on file, last reported at $20.1 million in Q1 2026.
- Quarterly Assets Average fell 76.49% year-over-year to $20.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.1 million (down 76.49% YoY) and the FY2025 annual result came in at $64.7 million, down 52.9% from the prior year.
- Assets Average eased to $20.1 million in Q1 2026, from $25.2 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $432.7 million in Q1 2022 to a low of $20.1 million in Q1 2026.
- A 5-year average of $200.5 million and a median of $165.4 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average declined 11.28% — and 2025, when it plunged 79.98%.
- Tracing ATRA's Assets Average over 5 years: stood at $372.4 million in 2022, then slumped by 52.43% to $177.1 million in 2023, then retreated by 28.93% to $125.9 million in 2024, then sank by 79.98% to $25.2 million in 2025, then slipped by 20.18% to $20.1 million in 2026.
- The last three Assets Average figures came in at $20.1 million (Q1 2026), $25.2 million (Q4 2025), and $33.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.29 Bn | 132.43 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.58 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.87 Bn | 56.73 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.90 Bn | 10.51 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 19.82 Bn |
| 10 | Atara Biotherapeutics | 146.12 Mn | 129.57 Mn | 439,000.00 | 20.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.51 Mn |
| Mar 31, 2026 | 20.12 Mn |
| Dec 31, 2025 | 25.20 Mn |
| Sep 30, 2025 | 33.53 Mn |
| Jun 30, 2025 | 49.47 Mn |
| Mar 31, 2025 | 85.57 Mn |
| Dec 31, 2024 | 125.90 Mn |
| Sep 30, 2024 | 130.00 Mn |
| Jun 30, 2024 | 141.28 Mn |
| Mar 31, 2024 | 165.39 Mn |
| Dec 31, 2023 | 177.15 Mn |
| Sep 30, 2023 | 217.61 Mn |
| Jun 30, 2023 | 274.26 Mn |
| Mar 31, 2023 | 339.25 Mn |
| Dec 31, 2022 | 372.37 Mn |
| Sep 30, 2022 | 402.22 Mn |
| Jun 30, 2022 | 416.70 Mn |
| Mar 31, 2022 | 432.70 Mn |
| Dec 31, 2021 | 459.03 Mn |
| Sep 30, 2021 | 453.36 Mn |